Certara (NASDAQ:CERT – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.410-0.460 for the period, compared to the consensus earnings per share estimate of 0.430. The company issued revenue guidance of $385.0 million-$400.0 million, compared to the consensus revenue estimate of $391.0 million.
Certara Stock Down 0.3 %
Shares of NASDAQ CERT opened at $12.25 on Friday. The stock has a market cap of $1.97 billion, a P/E ratio of -31.41, a P/E/G ratio of 5.39 and a beta of 1.52. The firm has a 50 day moving average price of $14.09 and a 200 day moving average price of $16.05. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.26 and a current ratio of 3.26. Certara has a 52-week low of $11.70 and a 52-week high of $19.87.
Certara (NASDAQ:CERT – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The firm had revenue of $93.31 million for the quarter, compared to analyst estimates of $96.01 million. Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 EPS. Analysts expect that Certara will post 0.28 EPS for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on CERT
Certara Company Profile
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Featured Articles
- Five stocks we like better than Certara
- Health Care Stocks Explained: Why You Might Want to Invest
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
- How to Use the MarketBeat Stock Screener
- Why Dell Can Continue Winning in AI and Beyond
- The Significance of Brokerage Rankings in Stock Selection
- MarketBeat Week in Review – 8/26 – 8/30
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.